What is the appropriate weight‑based IV bolus dosing of tenecteplase for acute massive or submassive pulmonary embolism, including contraindications, monitoring, and follow‑up recommendations?

Tenecteplase Dosing in Pulmonary Embolism

For acute massive (high-risk) pulmonary embolism with hemodynamic instability, administer weight-based tenecteplase as a single IV bolus: 30 mg for <60 kg, 35 mg for 60-69 kg, 40 mg for 70-79 kg, 45 mg for 80-89 kg, and 50 mg for ≥90 kg 1. This is the same dosing regimen FDA-approved for myocardial infarction and studied in PE trials 2, 3.

Indications by PE Risk Category

High-Risk (Massive) PE

• Systemic thrombolysis is recommended for patients with hemodynamic instability (shock or persistent hypotension) 4
• Tenecteplase provides the advantage of single bolus administration over alteplase's 2-hour infusion 5
• The 2011 AHA Scientific Statement supports fibrinolysis for "massive pulmonary emboli with unstable hemodynamics" 5
• Number needed to treat to prevent death or recurrent PE in massive PE is 10 5

Intermediate-Risk (Submassive) PE

• Routine primary thrombolysis is NOT recommended for hemodynamically stable patients with RV dysfunction 4
• The 2019 ESC Guidelines give this a Class III recommendation (should not be done) 4
• Reserve thrombolysis as rescue therapy if hemodynamic deterioration occurs despite anticoagulation 4
• While one trial showed improved composite outcomes with tenecteplase in submassive PE 3, this included one fatal intracranial hemorrhage, and guidelines prioritize avoiding harm in stable patients

Low-Risk PE

• Thrombolysis is contraindicated 4
• Anticoagulation alone is the standard of care

Administration Protocol

Preparation and Delivery:

• Reconstitute 50 mg vial with 10 mL sterile water to achieve 5 mg/mL concentration 1
• Administer as single IV bolus over 5-10 seconds
• Do NOT mix with other medications in the same line

Concurrent Anticoagulation:

• Start unfractionated heparin (UFH) immediately 4, 2
• For patients <67 kg: 4000 unit bolus, then 800 U/hr infusion
• For patients ≥67 kg: 5000 unit bolus, then 1000 U/hr infusion 1
• Target aPTT 50-75 seconds 1
• Continue heparin for 48-72 hours, then transition to oral anticoagulation

Absolute Contraindications

Do not administer tenecteplase if:

• Active internal bleeding
• History of intracranial hemorrhage or structural vascular abnormality
• Intracranial or intraspinal surgery within 2 months
• Severe uncontrolled hypertension
• Ischemic stroke within 3 months (except acute ischemic stroke within appropriate window)
• Known bleeding diathesis
• Current intracranial neoplasm

Monitoring Requirements

Immediate (First 24 Hours):

• Continuous cardiac monitoring and vital signs every 15 minutes for first hour, then hourly
• Serial echocardiography to assess RV function improvement (expect 30-35% reduction in perfusion defect at 24 hours vs. 0% with heparin alone) 5
• Monitor for bleeding complications at all puncture sites
• Neurological assessments every 2 hours for signs of intracranial hemorrhage
• Serial hemoglobin/hematocrit every 6-8 hours
• aPTT monitoring for heparin titration

Days 2-7:

• Daily clinical assessment for recurrent PE symptoms (dyspnea, chest pain, hemoptysis)
• Repeat echocardiography at 5-7 days (expect 65-70% reduction in perfusion defect, similar to heparin alone by this timepoint) 5
• Continue monitoring for delayed bleeding complications

Bleeding Risk Management

Major Bleeding Rates:

• The number needed to harm for major bleeding is 8-17 depending on PE severity 5
• Intracranial hemorrhage risk is approximately 0.9% 1
• Risk increases significantly in patients >65 years (41% of patients in trials were elderly with higher bleeding rates) 1

If Major Bleeding Occurs:

• Stop heparin immediately
• Administer cryoprecipitate (10 units) and tranexamic acid (1 g IV)
• Consider prothrombin complex concentrate
• Obtain emergent imaging if intracranial hemorrhage suspected

Special Populations and Dosing Considerations

Elderly Patients (≥65 years):

• Use standard weight-based dosing but maintain heightened vigilance for bleeding 1
• Consider reduced-dose regimens (e.g., 17.5 mg or 0.37 mg/kg) in very elderly patients (>90 years) with successful outcomes reported 6

Cardiac Arrest:

• Tenecteplase can be administered during CPR for suspected massive PE 7
• Continue CPR for at least 45-60 minutes post-administration to allow drug effect 7

Alternative Approaches

If thrombolysis contraindicated or fails:

• Surgical embolectomy (Class IIa recommendation) 4
• Catheter-directed therapy (Class IIa recommendation) 4
• ECMO in combination with surgical/catheter intervention for refractory collapse 4

Critical Pitfalls to Avoid

1. Do not use tenecteplase routinely in submassive PE - The bleeding risk outweighs benefit in hemodynamically stable patients 4
2. Do not delay anticoagulation - Start heparin immediately while preparing thrombolytic 4
3. Do not use GP IIb/IIIa inhibitors within 24 hours of tenecteplase administration 1
4. Do not underdose - Use full weight-based dosing for massive PE (this is TWICE the stroke dose) 8
5. Do not give IM injections or perform arterial punctures for 24 hours post-thrombolysis

Pharmacokinetics Relevant to Clinical Use

• Terminal half-life: 90-130 minutes 1
• Fibrinogen decreases 4-15% and plasminogen decreases 11-24% after administration 1
• Linear pharmacokinetics across 30-50 mg dose range 1
• Liver metabolism is primary clearance mechanism 1